Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 19/20 | 1.00 |
| ▸ | NOS3 | P29474 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31181448 | 1.00 | MAP3K12 (1.00) | MAP3K12NOS3NOS1NOS2 | |
| SCHEMBL16220051 | 0.92 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL16220378 | 0.89 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL16220201 | 0.88 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL16220380 | 0.87 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL16220381 | 0.86 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL16220200 | 0.85 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL17523098 | 0.82 | MAP3K12 (0.70) | MAP3K12 | |
| SCHEMBL16220379 | 0.82 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL16220057 | 0.81 | MAP3K12 (0.83) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2020132045-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEUROPROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | MAP3K12 1654/4885NOS3 3273/4885NOS1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.